Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Safety and Feasibility Assessment of the Bio-electrical One Day Capsule System in Overweight and Class I Obese Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03734081
Recruitment Status : Suspended (The first cohort of 6 subjects that has been enrolled is being analyzed and evaluated on all safety parameters as described in the study protocol.)
First Posted : November 7, 2018
Last Update Posted : August 15, 2019
Sponsor:
Information provided by (Responsible Party):
Melcap Systems Ltd.

Brief Summary:
The study represents the first effort to prospectively investigate the Melcap's bio-electrical ingestible ODC system in human. The study goal is to evaluate the safety and feasibility of GES treatment in stomach and in the small and large bowel during and following the ingestion of the bio-electrical capsule under tight and controlled conditions.

Condition or disease Intervention/treatment Phase
Overweight and Obesity Device: ODC system (type 1 capsule) Device: ODC system (type 2 capsule) Not Applicable

Detailed Description:

The problem of obesity in the adult population requires the exploration and development of new, safe and effective therapies to combat increasing growth. A novel Implantable Gastric Electrical Stimulation (GES), MEASTRO(R) Rechargeable System, has been recently approved by the American Food and Drug Administration (FDA) for use in weight reduction in patients aged 18 years through adulthood who have a Body Mass Index (BMI) of 40 to 45 kg/m2 with one or more obesity related co-morbid conditions, and have failed at least one supervised management program within the past 5 years.

Melcap System Ltd. has developed an innovative ingestible capsule system device that uses GES for the treatment of overweight and obesity. The system is intended to suppress hunger, reduce appetite, increase satiation and promote weight reduction in overweight and class I obese adults who have a Body Mass Index of 27 kg/m2 to 34.9 kg/m2 with no related co-morbid conditions.

The study is a FIH prospective, open label, randomized study. It will include a 3 days screening period and 4 days treatment session under a close supervision and follow up. Each subject will ingest a total of 2 capsules (ODC) on the first and the third day of the study. The total duration of subject participation including the termination visit will be eight days.

The study will be conducted at a single medical center, Meir Hospital, Israel.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A First in Human (FIH) Study to Assess the Safety and Feasibility of the Bio-electrical One Day Capsule (ODC) System (Type 1 and 2 Capsules) in Overweight and Class 1 Obese Subjects
Actual Study Start Date : February 4, 2019
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : March 2020

Arm Intervention/treatment
Experimental: Gastric electrical stimulation with type 2 ODC
Safety and feasibility assessment of the ODC system (type 2) capsule during and following gastric electrical stimulation protocol.
Device: ODC system (type 2 capsule)
ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.

Experimental: Electrical stimulation with type 2 ODC
Safety and feasibility assessment of the ODC system (type 2) capsule during and following small and large bowel electrical stimulation protocol.
Device: ODC system (type 2 capsule)
ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.

Experimental: Electrical stimulation with type 1 ODC
Safety and feasibility assessment of the ODC system (type 1 capsule) during and following small and large electrical stimulation protocol.
Device: ODC system (type 1 capsule)
ODC (one day capsule) type 1 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.




Primary Outcome Measures :
  1. Occurrence and severity of all adverse events [ Time Frame: During the whole study duration (approximately 8 days) ]
    Safety evaluation

  2. Incidence of device-related adverse events [ Time Frame: During the whole study duration (approximately 8 days) ]
    Safety evaluation

  3. Incidence of clinically significant abnormal laboratory values as determined by the investigator [ Time Frame: During the whole study duration (approximately 8 days) ]
    Safety evaluation

  4. Excretion of the study capsules in a natural manner [ Time Frame: up to 3 days after the days of the capsules ingestion ]
    Safety evaluation - confirmation of the capsule excretion from the body


Secondary Outcome Measures :
  1. Satiety levels [ Time Frame: Day #1 and #3 of the treatment period ]
    Changes in satiety levels resulting of the electrical stimulation

  2. Appetite levels [ Time Frame: Day #1 and #3 of the treatment period ]
    Changes in appetite levels resulting of the electrical stimulation

  3. Postprandial symptoms [ Time Frame: Day #1, #2, #3 and #4 of the treatment period ]
    Evaluation of postprandial symptoms during the treatment period

  4. Response to nutrient drink test [ Time Frame: Day #3 of the screening period and and day #4 of the treatment period ]
    Determination of the maximum tolerable drinking volume followed by postprandial symptoms measurement

  5. Appetite-related hormone [ Time Frame: Day #1 and Day #3 of the treatment period ]
    Evaluation of appetite- related hormones levels change as a result of the stimulation applied



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age of 21-65 years old at time of screening
  2. Body mass Index (BMI) >= 27 and <35
  3. The subject has been under routine care of the investigator or another single physician that can supply a medical record for at least 4 months prior to enrollment
  4. Female subjects at reproductive age that are tested negative for pregnancy
  5. Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods during the whole study duration
  6. No significant weight loss (<5%) within four months prior to enrollment (by self -report)
  7. No recorded or treated psychological disorder(s) for at least six months prior to enrollment (by self report)
  8. Not taking anti-depressant medication, for at least six months prior to enrollment.
  9. Willingness to refrain from using prescription, over the counter or herbal weight loss products for the duration of he trial.
  10. Personally motivated and willing to comply with all the requirements of the clinical trial
  11. Able to understand, read and voluntary sign the inform consent form
  12. Agree and able to sign the consent form for the Pillcam(R) patency capsule test as is in use at Meir MC.

Exclusion Criteria:

  1. History o abdominal or gastrointestinal surgery (appendectomy, hernia repair, gynecological surgeries and cholecystectomy more than a year ago are allowed)
  2. Prior bariatric surgery
  3. Implanted electrical stimulation devices (e.g. pacemaker, defibrillator, neurostimulator)
  4. Unwillingness to stop medication altering gastric pH and/or affecting GI motility during the entire study duration.
  5. Known diagnosed psychiatric conditions that may impair subject's ability to comply with the study procedures (by self-report)
  6. Use of anti-psychotic medications
  7. Diagnosed with an eating disorder including bulimia and binge eating
  8. Swallowing difficulties
  9. Significant active or unstable acute or chronic illnesses/ diseases including gastrointestinal, systemic (non-gastrointestinal) and psychiatric conditions
  10. Use of another investigation device or agent in the 30 days prior to enrollment
  11. Women who are pregnant, lactating or anticipate to becoming pregnant within the study duration
  12. Planned or contemplated use of Magnetic Resonance Imaging (MRI) or any (e.g. oncologic) radiation during the course of the trial.
  13. Have a family member who is currently participating in this clinical trial
  14. Any other conditions that, in the opinion of the investigator, would make the subject unsuitable for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03734081


Locations
Layout table for location information
Israel
Meir Medical Center
Kfar Saba, Israel, 4428164
Sponsors and Collaborators
Melcap Systems Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Timna Naftali, MD Meir Medical Center

Layout table for additonal information
Responsible Party: Melcap Systems Ltd.
ClinicalTrials.gov Identifier: NCT03734081    
Other Study ID Numbers: CLD-012
First Posted: November 7, 2018    Key Record Dates
Last Update Posted: August 15, 2019
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Overweight
Body Weight
Signs and Symptoms